A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate


Ruperto N., Murray K., Gerloni V., Wulffraat N., de Oliveira S., Falcini F., ...Daha Fazla

ARTHRITIS AND RHEUMATISM, cilt.50, ss.2191-2201, 2004 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 50 Konu: 7
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1002/art.20288
  • Dergi Adı: ARTHRITIS AND RHEUMATISM
  • Sayfa Sayıları: ss.2191-2201

Özet

Objective. To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15mg/m(2)/week) versus a higher dosage (30 mg/m(2)/ week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/ week).